[{"id":"db802908-d352-4788-a1a5-ab4e959f4c3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03009240","created_at":"2024-03-12T22:20:15.146Z","updated_at":"2024-07-02T16:35:15.595Z","phase":"Phase 1","brief_title":"Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia","source_id_and_acronym":"NCT03009240","lead_sponsor":"City of Hope Medical Center","biomarkers":" MIR155 • NFKB1","pipe":" | ","alterations":" miR-155 expression • NFKB1 expression","tags":["MIR155 • NFKB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e miR-155 expression • NFKB1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/21/2017","start_date":" 08/21/2017","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-03-08"},{"id":"fe98e2d0-590c-4f9c-b62c-d6aca24eea9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015815","created_at":"2023-08-29T16:10:13.927Z","updated_at":"2024-07-02T16:35:38.717Z","phase":"","brief_title":"The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT","source_id_and_acronym":"NCT06015815","lead_sponsor":"Ankara University","biomarkers":" MIR155 • MIR21","pipe":" | ","alterations":" miR-155 expression","tags":["MIR155 • MIR21"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e miR-155 expression"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 10/05/2019","start_date":" 10/05/2019","primary_txt":" Primary completion: 04/29/2020","primary_completion_date":" 04/29/2020","study_txt":" Completion: 08/15/2020","study_completion_date":" 08/15/2020","last_update_posted":"2023-08-29"}]